论文部分内容阅读
目的观察紫杉醇联合卡铂(TC)治疗晚期食管癌的疗效及毒副反应。方法 33例晚期食管癌患者,给予TC方案化疗:紫杉醇175 mg/m2,静脉滴注,第1天;卡铂AUC 5,静脉滴注,第2天,21 d为1个周期。结果 33例患者均可评价疗效,总有效率42.4%,疾病控制率57.6%,中位无进展生存期4.0个月,中位总生存期10.2个月。其中初治组有效率为50.0%,中位无进展生存期4.8个月,中位生存期11.5个月;复治组有效率为27.3%,中位无进展生存期2.8个月,中位生存期8.6个月。Ⅲ～Ⅳ度毒副反应主要为骨髓抑制(36.3%),无治疗相关性死亡。结论紫杉醇联合卡铂方案是晚期食管癌的有效治疗方案之一,毒副反应可耐受。
Objective To observe the efficacy and side effects of paclitaxel combined with carboplatin (TC) in the treatment of advanced esophageal cancer. Methods 33 cases of advanced esophageal cancer patients were given TC chemotherapy: paclitaxel 175 mg / m2, intravenous drip, the first day; carboplatin AUC 5, intravenous drip, the first two days, 21 d for a cycle. Results All the 33 patients could evaluate the curative effect, the total effective rate was 42.4%, disease control rate was 57.6%, the median progression-free survival was 4.0 months, and the median overall survival was 10.2 months. Among them, the effective rate of initial treatment group was 50.0%, the median progression-free survival period was 4.8 months and the median survival time was 11.5 months; the effective rate of retreatment group was 27.3%, the median progression-free survival period was 2.8 months and the median survival time Period of 8.6 months. Ⅲ ~ Ⅳ degrees of toxicity mainly bone marrow suppression (36.3%), no treatment-related deaths. Conclusion paclitaxel combined with carboplatin is one of the effective treatment options for advanced esophageal cancer. Toxicity and side effects can be tolerated.